Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2015 / Article
Special Issue

Dietary Polyphenols and Their Effects on Cell Biochemistry and Pathophysiology 2014

View this Special Issue

Review Article | Open Access

Volume 2015 |Article ID 950890 | https://doi.org/10.1155/2015/950890

Tiejun Zhao, Qiang Sun, Maud Marques, Michael Witcher, "Anticancer Properties of Phyllanthus emblica (Indian Gooseberry)", Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 950890, 7 pages, 2015. https://doi.org/10.1155/2015/950890

Anticancer Properties of Phyllanthus emblica (Indian Gooseberry)

Academic Editor: Tullia Maraldi
Received25 Sep 2014
Revised22 Dec 2014
Accepted24 Dec 2014
Published09 Jun 2015


There is a wealth of information emanating from both in vitro and in vivo studies indicating fruit extract of the Phyllanthus emblica tree, commonly referred to as Indian Gooseberries, has potent anticancer properties. The bioactivity in this extract is thought to be principally mediated by polyphenols, especially tannins and flavonoids. It remains unclear how polyphenols from Phyllanthus emblica can incorporate both cancer-preventative and antitumor properties. The antioxidant function of Phyllanthus emblica can account for some of the anticancer activity, but clearly other mechanisms are equally important. Herein, we provide a brief overview of the evidence supporting anticancer activity of Indian Gooseberry extracts, suggest possible mechanisms for these actions, and provide future directions that might be taken to translate these findings clinically.

1. Introduction

Cancer is a global epidemic with approximately fourteen million new cases being diagnosed each year, leading to an annual death toll of approximately eight million [1]. The societal burden resulting from such staggering numbers is almost immeasurable when one considers both the economic impact and quality of life consequences. However, a recent study puts the economic impact for individual cancers in the billions of dollars for Europe alone [2]. Obviously, more effective therapies are needed for many common cancers. But the holy grail of cancer research would be to identify either pharmacologic or lifestyle interventions that could prevent the onset of cancer. Towards this goal, research has shown that maintaining a healthy lifestyle decreases the risk of some cancers, and intake of some foods may also decrease risk [36]. Here, we will focus on the anticancer properties of the fruit-bearing tree Phyllanthus emblica.

Phyllanthus emblica is a tree indigenous to tropical regions of Southeast Asia. The tree produces a fruit commonly known as Indian Gooseberry or Amla. The Phyllanthus emblica fruit (also known as Emblica officinalis) or extract from these fruits has been used in traditional medicine for generations to treat symptoms ranging from constipation to the treatment of tumors [7]. Most commonly, the gooseberry was employed as a gentle laxative. However, the potential of Phyllanthus emblica extract to be utilized as an anticancer agent has been scrutinized using modern medical techniques over the past two decades. To date, there is substantial evidence that these extracts contain small molecules with both cancer-preventative and antitumor activity. Here, we will provide an overview of the literature supporting these concepts and attempt to lend insight into possible mechanisms whereby the anticancer properties are achieved.

2. Cancer Prevention

Each day we are exposed to agents in our environment and through our diet that can potentially compromise the integrity of our genome. Many xenobiotics and the reactive oxygen species generated during cell respiration are carcinogenic. Thus, reducing our exposure to harmful xenobiotics and increasing our capacity to “soak up” reactive oxygen species represented a potential means to reduce the likelihood of cancer. Using the classic measure of carcinogenicity, the Ames test, it was clearly demonstrated that Emblica officinalis prevents mutagenesis in vitro [8]. Proving this concept in vivo is not as straightforward. Measuring cancer prevention in humans is a time consuming and complex endeavor, involving many confounding factors. Fortunately, chemopreventive properties of substances can be tested using rodent models of various cancers.

Taken prophylactically, Emblica officinalis extract reduced the genotoxic effects of heavy metals and the carcinogen benzopyrene in murine models [9, 10]. In a murine model of skin carcinogenesis, continuous administration of Emblica officinalis extract at 100 mg/kg reduced tumor incidence by ~60% [11]. Similarly, two independent studies showed the polyphenol or aqueous fractions of Emblica officinalis administered at 60–250 mg/kg prevented N-nitrosodiethylamine induced hepatocellular carcinoma by ~80–100% [12, 13]. However, such dramatic results were not reported when Emblica officinalis extract was examined for chemoprevention of liver tumors induced by initiation with diethylnitrosamine followed by promotion with 2-acetylaminofluorene [14]. This difference indicates Emblica officinalis has the capacity to prevent the onset of some, but not all cancers, depending on the initiator. This becomes fairly obvious when one considers carcinogenic compounds have differing modes of action; thus a single extract could not be expected to be universally chemopreventive. Hopefully, future studies will expand on these studies to examine the ability of Emblica officinalis to prevent tumors initiated by a wider variety of carcinogens at diverse tissue sites.

How are these extracts chemopreventive? There are four possibilities. First, Phyllanthus emblica has potent free radical scavenging activities that might prevent reactive oxygen species induced DNA damage and oncogenesis [15, 16]. However, in the animal models described above, it is unclear to what extent reactive oxygen species contribute to the underlying pathology, implying that there may be alternative mechanisms of action. Second, the extract has properties allowing it to reduce the levels of cytochrome enzymes in liver cells [17]. Cytochromes, such as Cyp 450, convert xenobiotics to potentially carcinogenic substances in an effort to clear them from the body. However, this concept is controversial as Amla extract was not found to decrease Cyp 450 levels in at least two other studies [18, 19]. Third, Phyllanthus emblica extracts have anti-inflammatory activities that might prevent inflammation related cancers [20]. Finally, as we will describe below, Phyllanthus emblica harbors potent antitumor activity [21, 22]. Even exposure to low levels of extract from these berries may be enough to impair tumor progression at early stages. It should be noted that there is concern regarding potential hepatotoxicity after long term Amla ingestion [23]. This matter may need to be resolved in the future by clinical and epidemiological studies before Phyllanthus emblica extract can be safely recommended for long term consumption for the prevention of cancer.

3. Cancer Therapy

Phyllanthus emblica extracts have been demonstrated to have potent tumor repressive properties against a number of cancer types both in vitro and in vivo. Preclinical evidence using a diverse panel of cancer cell lines shows aqueous extract from Phyllanthus emblica berries induced apoptosis at concentrations ranging from 50 to 100 micrograms/mL [24]. In this study, normal fibroblasts were also included and showed 4-fold lower sensitivity to these extracts. This is in keeping with our own data comparing aqueous Phyllanthus emblica berry extracts (generous gift of Sabinsa Corporation) against triple-negative breast cancer cells (Figures 1(a) and 1(b)). We see exposure of these cells to doses of the soluble extract ranging from 25 to 100 micrograms/mL results in significant cytotoxicity (Figures 1(a) and 1(b)), but almost no effect is seen against normal breast epithelial cells (MCF10A). Other reports have shown extracts from blueberries and strawberries both limit the proliferation of triple-negative breast cancer cells in vitro and in vivo [25, 26]. However, neither of these extracts showed a considerable degree of antiproliferative activity at concentrations lower than 500 micrograms/mL, whereas soluble Phyllanthus emblica berry extract was potent even at 50 micrograms/mL in at least three (MDA-MB-231, MDA-MB-435, and MDA-MB-468) of the cell lines we tested. The sparsity of cells after exposure to the berry extract and appearance of debris indicate cells are undergoing apoptosis as opposed to cytostatic mechanisms of growth arrest. These data indicate Phyllanthus emblica extract or a constituent therein represents a potential treatment for breast cancer with low toxicity against nontransformed cells.

Phyllanthus emblica berry extract enriched for polyphenols or simple aqueous extracts have also shown cytotoxic activity against cervical and ovarian cancer cells [27, 28]. However, unlike other model systems tested, the reduced proliferation in ovarian cancer cells was attributed to the action of the autophagy pathway, independent of apoptosis [27]. Notably, in contrast to the studies outlined above where Phyllanthus emblica prevented liver carcinogenesis, in vitro studies using the human liver cancer cell line HepG2 show little evidence of cytotoxicity of aqueous extracts [29]. Overall, it appears that Phyllanthus emblica extract displays potent cytotoxic effects against most cell lines, but primary resistance mechanisms exist, as is seen with the Hs578T cell line (Figure 1(a)). Such resistant cells may prove to be a useful tool in determining the mechanism whereby these extracts carry out their cytotoxic effects.

In contrast to the in vitro studies, there is sparse evidence regarding the tumor repressive activity of Phyllanthus emblica using in vivo models of cancer. Such preclinical models are necessary for the translation of these investigations into something clinically relevant. However, a striking study has been carried out employing aqueous extracts of the Indian Gooseberry administered orally against an ovarian cancer xenograft model [27]. In this report, the extracts were able to completely ablate the growth of ovarian xenografts, with little or no residual tumor being observed after treatment. Clearly, these remarkable data warrant further investigation into the in vivo anticancer properties of Emblica officinalis extracts.

4. So, What Is in There?

Extracts from Phyllanthus emblica tree have been documented to have a number of disparate properties including antioxidant, anti-inflammatory, proapoptotic, and proautophagy ones [21, 27, 30, 31]. Obviously these berry extracts are a complex mix of compounds [22, 32] and it is not trivial to decipher which molecules mediate these effects. It may be that combinations of molecules from these berries work in synergy with one another to achieve diverse biological activity. Highly purified fractions of low complexity are needed from Phyllanthus emblica to be interrogated for each biological property. That being said, some of the known molecules held within the Indian Gooseberryextract, identified by high pressure liquid chromatography (HPLC), can be matched to its anticancer activity [22, 32, 33]. This review will focus on molecules identified by HPLC from Phyllanthus emblica extract that have reproducibly been shown to have anticancer properties. Primarily, we will focus on the hydrolyzable tannin content of these extracts because of their high content within the Amla fruit [22] and importantly due to their known antioxidant, cancer-preventative, and cytotoxic activity in vivo [34, 35]. However, the flavonoid quercetin perhaps serves as the best paradigm for the future drug development from molecules within Amla extract having anticancer properties (described below), as this molecule has gone to clinical trial and novel analogues are being pursued. While there are other constituents of Amla extract such as vitamin C that have antioxidant activity, the only molecules having bona fide anticancer activity to date fall within the tannin or flavonoid categories.

The major constituents of Phyllanthus emblica that have been identified by HPLC and formally characterized as having anticancer activity are described below (and in Table 1). Overall, it seems reasonable that many of the anticancer properties of this fruit are derived from the tannin content. However, a notable exception to this concept is the flavonoid quercetin, which harbors potent antioxidant and anticancer properties as demonstrated utilizing multiple in vivo models of cancer including breast and leukemia [3638].

Phenolic compounds from Phyllanthus emblica extract identified by HPLC having anticancer propertiesCancer model utilized to identify antiproliferative and antitumor properties

Ellagic acid (tannin)Colon, prostate cell lines, and breast and prostate xenografts

Corilagin (tannin)Ovarian cancer cells, liver cancer cells, and hepatocarcinoma xenografts

Pyrogallol (tannin)Lung cancer cells, gastric cancer cells, and lung adenocarcinoma xenografts

Chebulagic acid (tannin)Retinoblastoma colon cancer, breast cancer, prostate cancer, and leukemia cancer cell lines

Gallic acid (tannin)Breast and lung cancer cell lines, some activity against lung cancer xenograft

Quercetin (flavonoid)Numerous cancer cell lines from multiple tissue types, transgenic murine model of breast cancer, leukemia xenograft, and phase I clinical trial

Phyllanthus emblica is rich in polyphenols and hydrolysable tannin derived compounds that act as antioxidants [22, 32]. Well-studied examples include ellagic acid, gallic acid, and chebulagic acid [3941]. These and other tannins from Phyllanthus emblica have been demonstrated to prevent mutagenesis and lipid peroxidation in response to carcinogens and reactive oxygen species [42]. It is likely that the combination of these compounds acting in synergy allows Amla extract to soak up free radicals with such efficiency and imparts the extracts with cancer-preventative properties. Alkylating carcinogens generate DNA mutations through carbon oxidation or conjugation reactions with nucleic acids [43]. It is likely that Phyllanthus emblica extract will reduce the oxidative damage induced mutations generated by such agents, but it remains to be seen whether conjugation reactions are also impaired.

There are also similarities between the proapoptotic and autophagy effects of Phyllanthus emblica extract and purified components. Most in vitro data indicate the antiproliferative effect of these extracts is mediated via activation of an apoptotic cascade. Interestingly, either crude Emblica officinalis extracts or purified components are capable of NF-kappaB inhibition [4447]. Tannins from Phyllanthus emblica impairing NF-kappaB inhibition include chebulagic acid, ellagic acid, and corilagin. All of them have been shown to have antiproliferative and proapoptotic properties against cancer cells [4850]. The same is true for gallic acid, a product of tannin hydrolysis, and major constituent of Amla extract [22]. NF-kappaB is an important survival factor in many cancers, and its inhibition leads to pervasive apoptosis [51, 52]. Thus, many of the anticancer properties of these extracts may be brought about through inhibition of this transcription factor binding with its cognate DNA binding elements. Further, NF-kappaB activation is also a potent inducer of inflammation [53] and again it is reasonable to think that the anti-inflammatory properties of the Amla extract are mediated by NF-kappaB inhibition. However, it should be noted that a least one of the Phyllanthus emblica components having potent in vivo antitumor activity, pyrogallol, is known to activate reactive oxygen species and NF-kappaB binding [54, 55]. NF-kappaB independent tumor suppression has been described for gallotannin, indicating alternative mechanisms for growth inhibition may be relevant depending on the tissue being targeted [34].

But what about the induction of autophagy? Cell death in response to chebulagic acid and the flavonoid quercetin has been linked to autophagy [27, 56]. Considering apoptosis is tightly linked to the autophagosome, it is likely that many of the tannins present in Phyllanthus emblica extract may activate the autophagy and apoptotic response simultaneously [57].

Similar to the tannins outlined in Table 1, quercetin also induces apoptosis and autophagy. However, distinct from tannins, quercetin exhibits a well-characterized inhibition of growth factor signaling pathways. This includes oncogenic signaling pathways such as the EGFR [58, 59]. Quercetin accomplishes this feat through inhibition of PI3K signaling, which plays a pivotal role in relaying oncogenic growth signals from the EGFR. Structural studies of the quercetin analog LY-29004 reveal its activity as a competitive inhibitor of ATP binding to the PI3K catalytic domain [60]. Of course, as is true for any inhibitor, Ly-29004 also has off-target effects, such as CKII inhibition [61], that may play a role in its repression of proliferation.

To become relevant to humans, preclinical data using mouse models of cancer are necessary to interrogate the in vivo potential of hydrolyzable tannins. In fact, a number of the components of Phyllanthus emblica extract have been demonstrated to have striking anticancer activity against currently incurable cancer using xenograft models. Pyrogallol ablates the growth of lung adenocarcinoma xenografts at only 75 μg/kg [54]. Gallotannin has shown significant tumor response against triple-negative breast cancers and cholangiocarcinoma [34, 62]. Xenograft models of pancreatic and triple-negative breast cancers showed considerable response to ellagic acid [48, 63]. Recent evidence also indicates ellagic acid may act as a prophylactic, protecting against the onset of prostate or breast cancer in animal models [64, 65]. Corilagin demonstrates high antitumor activity against hepatocellular carcinoma xenograft models at 15 mg/kg [66]. Gallic acid shows antitumor qualities against lung and osteosarcoma, but the impact may be not substantial enough to warrant future studies [67, 68].

The flavonoid quercetin has been demonstrated to attenuate tumor growth in multiple animal models. This includes xenograft model of leukemia and pancreatic cancer [38, 69]. Based on the well-defined mechanism of action and encouraging data using murine models, quercetin was tested in a phase I clinical trial where it showed antityrosine kinase activity in vivo [70]. Analogues of quercetin designed as more specific PI3K inhibitors also demonstrate potent antiproliferative activities. Such analogues of other small molecules found with the Amla extract may facilitate further development into clinical relevant drugs.

Overall, the data published to date highlights the enormous potential of naturally occurring molecules from Phyllanthus emblica as pharmacological agents for the treatment of cancer.

5. Future Perspective

For Phyllanthus emblica to become relevant clinically, it is imperative that the molecules mediating the antitumor effects of the plant be identified and even more potent, patentable derivatives synthesized. Without the possibility of patents, the pharmaceutical industry will undoubtedly not invest the enormous amount of money required to carry out clinical trials using these putative chemotherapeutics. Such evidenced-based trials will eventually be necessary to prove the worth of these extracts in preventing and treating human cancer.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at: Publisher Site | Google Scholar
  2. P. Hanly, I. Soerjomataram, and L. Sharp, “Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe,” International Journal of Cancer, vol. 136, no. 4, pp. E136–E45, 2015. View at: Publisher Site | Google Scholar
  3. G. A. Colditz and K. Bohlke, “Priorities for the primary prevention of breast cancer,” CA Cancer Journal for Clinicians, vol. 64, no. 3, pp. 186–194, 2014. View at: Publisher Site | Google Scholar
  4. C. C. Huang, W. T. Lee, S. T. Tsai et al., “Tea consumption and risk of head and neck cancer,” PLoS ONE, vol. 9, no. 5, Article ID e96507, 2014. View at: Publisher Site | Google Scholar
  5. L. Wang, X. Zhang, J. Liu, L. Shen, and Z. Li, “Tea consumption and lung cancer risk: a meta-analysis of case-control and cohort studies,” Nutrition, vol. 30, no. 10, pp. 1122–1127, 2014. View at: Publisher Site | Google Scholar
  6. A. H. Eliassen, S. J. Hendrickson, L. A. Brinton et al., “Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies,” Journal of the National Cancer Institute, vol. 104, no. 24, pp. 1905–1916, 2012. View at: Publisher Site | Google Scholar
  7. D. W. Unander, G. L. Webster, and B. S. Blumberg, “Records of usage or assays in Phyllanthus (Euphorbiaceae) I. Subgenera Isocladus, Kirganelia, Cicca and Emblica,” Journal of Ethnopharmacology, vol. 30, no. 3, pp. 233–264, 1990. View at: Publisher Site | Google Scholar
  8. N. Sharma, P. Trikha, M. Athar, and S. Raisuddin, “In vitro inhibition of carcinogen-induced mutagenicity by Cassia occidentalis and Emblica officinalis,” Drug and Chemical Toxicology, vol. 23, no. 3, pp. 477–484, 2000. View at: Publisher Site | Google Scholar
  9. P. Nandi, G. Talukder, and A. Sharma, “Dietary chemoprevention of clastogenic effects of 3,4-benzo(a)pyrene by Emblica officinalis Gaertn. fruit extract,” British Journal of Cancer, vol. 76, no. 10, pp. 1279–1283, 1997. View at: Publisher Site | Google Scholar
  10. H. Dhir, A. K. Roy, A. Sharma, and G. Talukder, “Modification of clastogenicity of lead and aluminium in mouse bone marrow cells by dietary ingestion of Phyllanthus emblica fruit extract,” Mutation Research, vol. 241, no. 3, pp. 305–312, 1990. View at: Publisher Site | Google Scholar
  11. G. Sancheti, A. Jindal, R. Kumari, and P. K. Goyal, “Chemopreventive action of Emblica officinalis on skin carcinogenesis in mice,” Asian Pacific Journal of Cancer Prevention, vol. 6, no. 2, pp. 197–201, 2005. View at: Google Scholar
  12. N. V. Rajeshkumar, M. R. Pillai, and R. Kuttan, “Induction of apoptosis in mouse and human carcinoma cell lines by Emblica officinalis polyphenols and its effect on chemical carcinogenesis,” Journal of Experimental and Clinical Cancer Research, vol. 22, no. 2, pp. 201–212, 2003. View at: Google Scholar
  13. K. J. Jeena, K. L. Joy, and R. Kuttan, “Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-nitrosodiethylamine induced hepatocarcinogenesis,” Cancer Letters, vol. 136, no. 1, pp. 11–16, 1999. View at: Publisher Site | Google Scholar
  14. S. Sultana, S. Ahmed, and T. Jahangir, “Emblica officinalis and hepatocarcinogenesis: a chemopreventive study in Wistar rats,” Journal of Ethnopharmacology, vol. 118, no. 1, pp. 1–6, 2008. View at: Publisher Site | Google Scholar
  15. B. Hazra, R. Sarkar, S. Biswas, and N. Mandal, “Comparative study of the antioxidant and reactive oxygen species scavenging properties in the extracts of the fruits of Terminalia chebula, Terminalia belerica and Emblica officinalis,” BMC Complementary and Alternative Medicine, vol. 10, article 20, 2010. View at: Publisher Site | Google Scholar
  16. M. Majeed, B. Bhat, A. N. Jadhav, J. S. Srivastava, and K. Nagabhushanam, “Ascorbic acid and tannins from Emblica officinalis Gaertn. Fruits—a revisit,” Journal of Agricultural and Food Chemistry, vol. 57, no. 1, pp. 220–225, 2009. View at: Publisher Site | Google Scholar
  17. S. M. Banu, K. Selvendiran, J. P. V. Singh, and D. Sakthisekaran, “Protective effect of Emblica officinalis ethanolic extract against 7,12-dimethylbenz(a)anthracene (DMBA) induced genotoxicity in Swiss albino mice,” Human and Experimental Toxicology, vol. 23, no. 11, pp. 527–531, 2004. View at: Publisher Site | Google Scholar
  18. K.-H. Chen, B.-R. Lin, C.-T. Chien, and C.-H. Ho, “Emblica officinalis gaertn. attentuates N-nitrosodiethylamine-induced apoptosis, autophagy, and inflammation in rat livers,” Journal of Medicinal Food, vol. 14, no. 7-8, pp. 746–755, 2011. View at: Publisher Site | Google Scholar
  19. S. A. Tasduq, D. M. Mondhe, D. K. Gupta, M. Baleshwar, and R. K. Johri, “Reversal of fibrogenic events in liver by Emblica officinalis (fruit), an Indian natural drug,” Biological and Pharmaceutical Bulletin, vol. 28, no. 7, pp. 1304–1306, 2005. View at: Publisher Site | Google Scholar
  20. M. Golechha, V. Sarangal, S. Ojha, J. Bhatia, and D. S. Arya, “Anti-inflammatory effect of Emblica officinalis in rodent models of acute and chronic inflammation: involvement of possible mechanisms,” International Journal of Inflammation, vol. 2014, Article ID 178408, 6 pages, 2014. View at: Publisher Site | Google Scholar
  21. M. S. Baliga and J. J. Dsouza, “Amla (Emblica officinalis Gaertn), a wonder berry in the treatment and prevention of cancer,” European Journal of Cancer Prevention, vol. 20, no. 3, pp. 225–239, 2011. View at: Publisher Site | Google Scholar
  22. B. Yang and P. Liu, “Composition and biological activities of hydrolyzable tannins of fruits of phyllanthus emblica,” Journal of Agricultural and Food Chemistry, vol. 62, no. 3, pp. 529–541, 2014. View at: Publisher Site | Google Scholar
  23. C. Wiart, “Note on the relevance of Emblica officinalis Gaertn. for the treatment and prevention of cancer,” European Journal of Cancer Prevention, vol. 22, no. 2, article 198, 2013. View at: Publisher Site | Google Scholar
  24. C. Ngamkitidechakul, K. Jaijoy, P. Hansakul, N. Soonthornchareonnon, and S. Sireeratawong, “Antitumour effects of Phyllanthus emblica L.: induction of cancer cell apoptosis and inhibition of in vivo tumour promotion and in vitro invasion of human cancer cells,” Phytotherapy Research, vol. 24, no. 9, pp. 1405–1413, 2010. View at: Publisher Site | Google Scholar
  25. L. S. Adams, S. Phung, N. Yee, N. P. Seeram, L. Li, and S. Chen, “Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway,” Cancer Research, vol. 70, no. 9, pp. 3594–3605, 2010. View at: Publisher Site | Google Scholar
  26. R. R. Somasagara, M. Hegde, K. K. Chiruvella, A. Musini, B. Choudhary, and S. C. Raghavan, “Extracts of strawberry fruits induce intrinsic pathway of apoptosis in breast cancer cells and inhibits tumor progression in mice,” PLoS ONE, vol. 7, no. 10, Article ID e47021, 2012. View at: Publisher Site | Google Scholar
  27. A. De, C. Papasian, S. Hentges, S. Banerjee, I. Haque, and S. K. Banerjee, “Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors,” PLoS ONE, vol. 8, no. 8, Article ID e72748, 2013. View at: Publisher Site | Google Scholar
  28. X. Zhu, J. Wang, Y. Ou, W. Han, and H. Li, “Polyphenol extract of Phyllanthus emblica (PEEP) induces inhibition of cell proliferation and triggers apoptosis in cervical cancer cells,” European Journal of Medical Research, vol. 18, no. 1, article 46, 2013. View at: Publisher Site | Google Scholar
  29. M. M. Shivananjappa and M. K. Joshi, “Influence of Emblica officinalis aqueous extract on growth and antioxidant defense system of human hepatoma cell line (HepG2),” Pharmaceutical Biology, vol. 50, no. 4, pp. 497–505, 2012. View at: Publisher Site | Google Scholar
  30. S. Rawal, P. Singh, A. Gupta, and S. Mohanty, “Dietary intake of Curcuma longa and Emblica officinalis increases life span in Drosophila melanogaster,” BioMed Research International, vol. 2014, Article ID 910290, 7 pages, 2014. View at: Publisher Site | Google Scholar
  31. S. Mahata, A. Pandey, S. Shukla et al., “Anticancer activity of Phyllanthus emblica Linn. (Indian Gooseberry): inhibition of transcription factor ap-1 and HPV gene expression in cervical cancer cells,” Nutrition and Cancer, vol. 65, supplement 1, pp. 88–97, 2013. View at: Publisher Site | Google Scholar
  32. E. A. Poltanov, A. N. Shikov, H. J. D. Dorman et al., “Chemical and antioxidant evaluation of Indian gooseberry (Emblica officinalis Gaertn., syn. Phyllanthus emblica L.) supplements,” Phytotherapy Research, vol. 23, no. 9, pp. 1309–1315, 2009. View at: Publisher Site | Google Scholar
  33. B. Yang, M. Kortesniemi, P. Liu, M. Karonen, and J.-P. Salminen, “Analysis of hydrolyzable tannins and other phenolic compounds in emblic leafflower (Phyllanthus emblica L.) fruits by high performance liquid chromatography-electrospray ionization mass spectrometry,” Journal of Agricultural and Food Chemistry, vol. 60, no. 35, pp. 8672–8683, 2012. View at: Publisher Site | Google Scholar
  34. T. Zhao, Q. Sun, S. V. Del Rincon, A. Lovato, M. Marques, and M. Witcher, “Gallotannin imposes S phase arrest in breast cancer cells and suppresses the growth of triple-negative tumors in vivo,” PLoS ONE, vol. 9, no. 3, Article ID e92853, 2014. View at: Publisher Site | Google Scholar
  35. Y. Chai, H.-J. Lee, A. A. Shaik et al., “Penta-O-galloyl-β-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of P21 cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple-negative xenograft growth,” Breast Cancer Research, vol. 12, no. 5, article R67, 2010. View at: Publisher Site | Google Scholar
  36. C. Spagnuolo, M. Russo, S. Bilotto, I. Tedesco, B. Laratta, and G. L. Russo, “Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia,” Annals of the New York Academy of Sciences, vol. 1259, no. 1, pp. 95–103, 2012. View at: Publisher Site | Google Scholar
  37. J. L. Steiner, J. M. Davis, J. L. McClellan et al., “Dose-dependent benefits of quercetin on tumorigenesis in the C3(1)/SV40Tag transgenic mouse model of breast cancer,” Cancer Biology & Therapy, vol. 15, no. 11, pp. 1456–1467, 2014. View at: Publisher Site | Google Scholar
  38. S. Cheng, N. Gao, Z. Zhang et al., “Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax,” Clinical Cancer Research, vol. 16, no. 23, pp. 5679–5691, 2010. View at: Publisher Site | Google Scholar
  39. A. Galano, M. Francisco Marquez, and A. Pérez-González, “Ellagic acid: an unusually versatile protector against oxidative stress,” Chemical Research in Toxicology, vol. 27, no. 5, pp. 904–918, 2014. View at: Publisher Site | Google Scholar
  40. M. Singh, A. Jha, A. Kumar, N. Hettiarachchy, A. K. Rai, and D. Sharma, “Influence of the solvents on the extraction of major phenolic compounds (punicalagin, ellagic acid and gallic acid) and their antioxidant activities in pomegranate aril,” Journal of Food Science and Technology, vol. 51, no. 9, pp. 2070–2077, 2014. View at: Publisher Site | Google Scholar
  41. A. Manosroi, P. Jantrawut, H. Akazawa, T. Akihisa, and J. Manosroi, “Biological activities of phenolic compounds isolated from galls of Terminalia chebula Retz. (Combretaceae),” Natural Product Research, vol. 24, no. 20, pp. 1915–1926, 2010. View at: Publisher Site | Google Scholar
  42. P. S. Makena and K.-T. Chung, “Effects of various plant polyphenols on bladder carcinogen benzidine-induced mutagenicity,” Food and Chemical Toxicology, vol. 45, no. 10, pp. 1899–1909, 2007. View at: Publisher Site | Google Scholar
  43. A. Dipple, “DNA adducts of chemical carcinogens,” Carcinogenesis, vol. 16, no. 3, pp. 437–441, 1995. View at: Publisher Site | Google Scholar
  44. R. Piva, L. Penolazzi, M. Borgatti et al., “Apoptosis of human primary osteoclasts treated with molecules targeting nuclear factor-kappaB,” Annals of the New York Academy of Sciences, vol. 1171, pp. 448–456, 2009. View at: Publisher Site | Google Scholar
  45. H.-H. Ho, C.-S. Chang, W.-C. Ho, S.-Y. Liao, C.-H. Wu, and C.-J. Wang, “Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-κB activity and downregulation of PI3K/AKT/small GTPase signals,” Food and Chemical Toxicology, vol. 48, no. 8-9, pp. 2508–2516, 2010. View at: Publisher Site | Google Scholar
  46. H. H. Ho, C.-S. Chang, W.-C. Ho, S.-Y. Liao, W.-L. Lin, and C.-J. Wang, “Gallic acid inhibits gastric cancer cells metastasis and invasive growth via increased expression of RhoB, downregulation of AKT/small GTPase signals and inhibition of NF-kappaB activity,” Toxicology and Applied Pharmacology, vol. 266, no. 1, pp. 76–85, 2013. View at: Publisher Site | Google Scholar
  47. L. Penolazzi, I. Lampronti, M. Borgatti et al., “Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalis,” BMC Complementary and Alternative Medicine, vol. 8, article 59, 2008. View at: Publisher Site | Google Scholar
  48. M. Edderkaoui, I. Odinokova, I. Ohno et al., “Ellagic acid induces apoptosis through inhibition of nuclear factor κB in pancreatic cancer cells,” World Journal of Gastroenterology, vol. 14, no. 23, pp. 3672–3680, 2008. View at: Publisher Site | Google Scholar
  49. P. Anitha, R. V. Priyadarsini, K. Kavitha, P. Thiyagarajan, and S. Nagini, “Ellagic acid coordinately attenuates Wnt/beta-catenin and NF-kappaB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis,” European Journal of Nutrition, vol. 52, no. 1, pp. 75–84, 2013. View at: Publisher Site | Google Scholar
  50. L. Jia, H. Jin, J. Zhou et al., “A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways,” BMC Complementary and Alternative Medicine, vol. 13, article 33, 2013. View at: Publisher Site | Google Scholar
  51. C. Gasparini, C. Celeghini, L. Monasta, and G. Zauli, “NF-kappaB pathways in hematological malignancies,” Cellular and Molecular Life Sciences, vol. 71, no. 11, pp. 2083–2102, 2014. View at: Publisher Site | Google Scholar
  52. H.-M. Shen and V. Tergaonkar, “NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy,” Apoptosis, vol. 14, no. 4, pp. 348–363, 2009. View at: Publisher Site | Google Scholar
  53. B. Hoesel and J. A. Schmid, “The complexity of NF-κB signaling in inflammation and cancer,” Molecular Cancer, vol. 12, no. 1, article 86, 2013. View at: Publisher Site | Google Scholar
  54. C.-J. Yang, C.-S. Wang, J.-Y. Hung et al., “Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in an animal model,” Lung Cancer, vol. 66, no. 2, pp. 162–168, 2009. View at: Publisher Site | Google Scholar
  55. I. M. Adcock, C. R. Brown, O. Kwon, and P. J. Barnes, “Oxidative stress induces NFκB DNA binding and inducible NOS mRNA in human epithelial cells,” Biochemical and Biophysical Research Communications, vol. 199, no. 3, pp. 1518–1524, 1994. View at: Publisher Site | Google Scholar
  56. H. J. Kim, J. Kim, K. S. Kang, K. T. Lee, and H. O. Yang, “Neuroprotective effect of chebulagic acid via autophagy induction in SH-SY5Y cells,” Biomolecules & Therapeutics, vol. 22, no. 4, pp. 275–281, 2014. View at: Publisher Site | Google Scholar
  57. D. M. Benbrook and A. Long, “Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis,” Experimental Oncology, vol. 34, no. 3, pp. 286–297, 2012. View at: Google Scholar
  58. L. T. Lee, Y. T. Huang, J. J. Hwang et al., “Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells,” Anticancer Research, vol. 22, no. 3, pp. 1615–1627, 2002. View at: Google Scholar
  59. F. A. Bhat, G. Sharmila, S. Balakrishnan et al., “Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway,” The Journal of Nutritional Biochemistry, vol. 25, no. 11, pp. 1132–1139, 2014. View at: Publisher Site | Google Scholar
  60. E. H. Walker, M. E. Pacold, O. Perisic et al., “Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine,” Molecular Cell, vol. 6, no. 4, pp. 909–919, 2000. View at: Publisher Site | Google Scholar
  61. S. P. Davies, H. Reddy, M. Caivano, and P. Cohen, “Specificity and mechanism of action of some commonly used protein kinase inhibitors,” Biochemical Journal, vol. 351, no. 1, pp. 95–105, 2000. View at: Publisher Site | Google Scholar
  62. C. Marienfeld, L. Tadlock, Y. Yamagiwa, and T. Patel, “Inhibition of cholangiocarcinoma growth by tannic acid,” Hepatology, vol. 37, no. 5, pp. 1097–1104, 2003. View at: Publisher Site | Google Scholar
  63. N. Wang, Z.-Y. Wang, S.-L. Mo et al., “Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer,” Breast Cancer Research and Treatment, vol. 134, no. 3, pp. 943–955, 2012. View at: Publisher Site | Google Scholar
  64. M. V. Vadhanam, S. Ravoori, F. Aqil, and R. C. Gupta, “Chemoprevention of mammary carcinogenesis by sustained systemic delivery of ellagic acid,” European Journal of Cancer Prevention, vol. 20, no. 6, pp. 484–491, 2011. View at: Publisher Site | Google Scholar
  65. A. Naiki-Ito, T. Chewonarin, M. Tang et al., “Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis,” The Prostate, vol. 75, no. 2, pp. 151–160, 2015. View at: Publisher Site | Google Scholar
  66. D. K.-P. Hau, G.-Y. Zhu, A. K.-M. Leung et al., “In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma,” Phytomedicine, vol. 18, no. 1, pp. 11–15, 2010. View at: Publisher Site | Google Scholar
  67. B. C. Ji, W. H. Hsu, J. S. Yang, and et al, “Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo,” Journal of Agricultural and Food Chemistry, vol. 57, no. 16, pp. 7596–7604, 2009. View at: Publisher Site | Google Scholar
  68. C.-Z. Liang, X. Zhang, H. Li et al., “Gallic acid induces the apoptosis of human osteosarcoma cells in vitro and in vivo via the regulation of mitogen-activated protein kinase pathways,” Cancer Biotherapy and Radiopharmaceuticals, vol. 27, no. 10, pp. 701–710, 2012. View at: Publisher Site | Google Scholar
  69. E. Angst, J. L. Park, A. Moro et al., “The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo,” Pancreas, vol. 42, no. 2, pp. 223–229, 2013. View at: Publisher Site | Google Scholar
  70. D. R. Ferry, A. Smith, J. Malkhandi et al., “Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition,” Clinical Cancer Research, vol. 2, no. 4, pp. 659–668, 1996. View at: Google Scholar

Copyright © 2015 Tiejun Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.